Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Atricure (ATRC) Stock Price & Analysis
332 Followers
ATRC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.94 - $59.61
Previous Close$24.17
Volume85.16K
Average Volume (3M)869.35K
Market Cap
$1.16B
Enterprise Value$1.11B
Total Cash (Recent Filing)$137.28M
Total Debt (Recent Filing)$74.49M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Jul 30, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding48,382,325
10 Day Avg. Volume1,065,659
30 Day Avg. Volume869,351
Standard Deviation0.12
R-Squared0.37
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)6.63
Price to Sales (P/S)2.78
Price to Cash Flow (P/CF)68.90
P/FCF Ratio89.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.77
Enterprise Value/Gross Profit3.68
Enterprise Value/Ebitda-151.92
Forecast
1Y Price Target
$44.78Price Target Upside86.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Atricure News
PremiumCompany Announcements
AtriCure Enhances Governance and Expands Stock Plan
Bulls Say, Bears Say
Bulls Say
Market PositionAtriCure's dominant position in open ablation provides substantial market share insulation for its Left Atrial Appendage device.
Revenue GrowthThe company is expected to meet its guidance for 15-17% revenue growth, which can be achieved given new products in the US and open ablation outside the US.
ValuationThe stock looks cheap and the recent pullback is seen as an opportunity for investors to BUY the stock.
Bears Say
Competitive PressureInvestors remain concerned with the potential impact of Medtronic's Penditure surgical left atrial appendage occlusion device on ATRC's US Appendage Management business.
Market UncertaintyThere is confusion and uncertainty in the market due to concerns about a competitive product.
Price TargetThe price target has been lowered to $40 from $46 due to peer multiple.
---
Ownership Overview
12.36% Insiders
43.12% Mutual Funds
16.48% Other Institutional Investors
28.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $59.61 in the past 12 months.
What is Atricure’s market cap?
Currently, no data Available
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Jul 30, 2024 which is in 8 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on May 01, 2024. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.229 by -$0.051.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -$0.17.
How many shares outstanding does Atricure have?
Atricure has 48,382,324 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.229. Following the earnings report the stock price went down -10.258%.
Which hedge fund is a major shareholder of Atricure?
Among the largest hedge funds holding Atricure’s share is Bridger Management, LLC. It holds Atricure’s shares valued at 3M.
---
Atricure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.78 (86.43% Upside)
$44.78 (86.43% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 10.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $111.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.73%
12-Months-Change
Fundamentals
Return on Equity
-8.17%
Trailing 12-Months
Asset Growth
1.46%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
---
ATRC Company Deck
---
ATRC Earnings Call
Q1 2024
0:00 / 0:00
---
ATRC Stock 12 Month Forecast
Average Price Target
$44.78
▲(86.43% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
18/20 ratings generated profit
1 Year Average Return
+42.10%
reiterated a buy rating 3 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +42.10% per trade.
---